WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

NCT01827137 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: Galinpepimut-S
BIOLOGICAL: GM-CSF
OTHER: Montanide
DRUG: lenalidomide
DRUG: bortezomib

Sponsor

Sellas Life Sciences Group

Collaborators

[object Object]